NVO Novo Nordisk A/S

-0.02  -0%
Previous Close 48.67
Open 48.74
Price To book 15.95
Market Cap 124057500000
Shares 2,550,000,000
Volume 855,798
Short Ratio 1.93
Av. Daily Volume 1,721,033

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
NDA filing resubmission noted March 29, 2017 in response to CRL issued October 2016. Estimated latest possible PDUFA date - September 29, 2017 using 6-month timeline. Waiting for official date from company.
Fast-acting insulin aspart
Type 1 and type 2 diabetes
Phase 3 completed.
Somapacitan (NN8640)
Adult Growth Hormone Deficiency (AGHD)
Phase 2 data released June 23, 2017 with Phase 3 trial to commence 2018.
Semaglutide (NN9536)
Phase 3 positive data released August 16, 2017 compared to treatment with dulaglutide.
Type 2 diabetes
Phase 2 ongoing.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
NDA filed December 5, 2016. PDUFA estimate December 5, 2017.
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B

Latest News

  1. A New CEO Only Emboldens the Case for Teva Pharmaceutical Industries Ltd (TEVA) Stock
  2. Novo Nordisk A/S : NVO-US: Dividend Analysis : August 21st, 2017 (record date) : By the numbers : September 18, 2017
  3. Wells Fargo Commercial Mortgage Trust 2016-NXS6 -- Moody's Affirms Seven Classes of WFCM 2016-NXS6
  4. The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
  5. Top Analyst Reports for Apple, Pfizer & Carnival
  6. Teva Rockets After Hiring Former Novo Nordisk Exec As CEO
  7. Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News
  8. Teva Pharmaceutical Industries Ltd ADR (TEVA) Names Kare Schultz As CEO
  9. Here's Why Novo Nordisk A/S Gained 12% in August
  10. Danish drugmaker reaches settlement with US authorities
  11. Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 mln
  12. Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
  13. Novo Nordisk Settles U.S. Suit Over Victoza for $58.65 Million
  14. Novo Nordisk's Tresiba Gets Canadian Nod
  15. Corporate News Blog - Novo Nordisk’s Victoza(R) Receives Approval from FDA
  16. ETFs with exposure to Novo Nordisk A/S : August 28, 2017
  17. Health Canada Approves Tresiba®, a New Basal Insulin for Type 1 and 2 Diabetes
  18. Novo Nordisk's Victoza Gets FDA Nod for Label Expansion
  19. FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk